Clinical Study to Investigate the Effectiveness of the TOPAS Sling System to Treat Fecal Incontinence (TRANSFORM)
This study is ongoing, but not recruiting participants.
Sponsor:
American Medical Systems
Information provided by (Responsible Party):
American Medical Systems
ClinicalTrials.gov Identifier:
NCT01090739
First received: March 19, 2010
Last updated: December 12, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to demonstrate that the TOPAS Sling System effectively treats fecal incontinence as measured by a 50% reduction in the number of FI episodes in a 14 day bowel diary at 12 months.
| Condition | Intervention |
|---|---|
|
Fecal Incontinence |
Device: TOPAS Sling System |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Investigation of the Treatment of Fecal Incontinence Using the TOPAS Sling System For Women (TRANSFORM) |
Resource links provided by NLM:
Further study details as provided by American Medical Systems:
Primary Outcome Measures:
- Efficacy [ Time Frame: 12 Months ] [ Designated as safety issue: No ]The primary endpoint for efficacy is the 14 day bowel diary documenting liquid or solid fecal incontinence episodes. A 50% reduction in the number of FI episodes is considered a treatment success.
| Enrollment: | 152 |
| Study Start Date: | April 2010 |
| Estimated Study Completion Date: | August 2016 |
| Estimated Primary Completion Date: | April 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: TOPAS
TOPAS Sling System Implant
|
Device: TOPAS Sling System
The TOPAS Sling System is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Subject is/has:
- An adult (>/= 18 years) female.
- FI symptoms for a minimum of 6 months.
- Failed two modalities of conservative therapies such as Dietary Modification, Pharmacologic Intervention, or Pelvic Floor Muscle Training.
- <50 years old OR if >/= 50 years old, has had a negative cancer screening examination of the colon according screening guidelines (colonoscopy or barium enema + flexible sigmoidoscopy) within the past 3 years prior to informed consent date. (Note: if not done, the investigating physician must provide written justification for not having this exam and must be following the American Cancer Society Guidelines).
- FI episodes ≥ 4 in 14 day period.
Exclusion Criteria:
Subject is/has
- Unable or unwilling to sign Informed Consent Form or comply with study requirements.
- Currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound the results of this study as determined by AMS.
- Allergic to polypropylene.
- Pregnant or planning a future pregnancy.
- Less than 12 months (365 days) postpartum.
- Pelvic prolapse >/=1 cm beyond the hymen (Stage III & IV)
- Had stress urinary incontinence (SUI) or anterior repair within 3 months (90 days) prior to TOPAS Sling System implantation.
- Had a hysterectomy, Sphincteroplasty, or Posterior surgery within 6 months (180 days) prior to TOPAS Sling System implantation.
- Had rectal surgery (such as rectopexy) within 12 months (365 days) of TOPAS Sling System implantation.
- Planning pelvic surgery within 12 months (365 days) post implant
- Current Grade III or IV hemorrhoids.
- Neurological or psychological condition as cause of FI such as MS, dementia, brain tumor.
- Diagnosed Inflammatory Bowel Disease (for example, ulcerative colitis or Crohn's disease).
- Chronic, watery diarrhea, unmanageable by drugs or diet, as primary cause of fecal incontinence.
- Severe chronic constipation, including obstructive defecatory disorder.
- External full thickness rectal prolapse.
- A history of laxative abuse within the past 5 years.
- Had previous rectal resection.
- Active pelvic infection, perianal or recto-vaginal fistula.
- Congenital anorectal malformations or chronic 4th degree lacerations and cloacae.
- History of therapeutic radiation for cancers of the pelvis.
- Currently implanted with a sacral nerve stimulator.
- Contraindicated for surgery or having any condition that would compromise wound healing.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01090739
Locations
| United States, California | |
| University of California SF - Mt Zion Medical Center | |
| San Francisco, California, United States, 94115 | |
| United States, Florida | |
| University of South Florida | |
| Tampa, Florida, United States, 33605 | |
| Cleveland Clinic Foundation - Florida | |
| Weston, Florida, United States, 33331 | |
| United States, Georgia | |
| Raybon OB-GYN | |
| Toccoa, Georgia, United States, 30577 | |
| United States, Michigan | |
| University of Michigan | |
| Ann Arbor, Michigan, United States, 48109 | |
| United States, Minnesota | |
| Abbott Northwestern Hospital | |
| Minneapolis, Minnesota, United States, 55407 | |
| United States, New Jersey | |
| Atlantic Health System | |
| Morristown, New Jersey, United States, 07960 | |
| United States, North Carolina | |
| University of North Carolina - Chapel Hill | |
| Chapel Hill, North Carolina, United States, 27599 | |
| United States, Ohio | |
| The Christ Hospital | |
| Cincinnati, Ohio, United States, 45219 | |
| Cleveland Clinic Foundation - Ohio | |
| Cleveland, Ohio, United States, 44195 | |
| United States, Oklahoma | |
| University of Oklahoma | |
| Oklahoma City, Oklahoma, United States, 76104 | |
| United States, Pennsylvania | |
| St. Luke's Hospital | |
| Allentown, Pennsylvania, United States, 18104 | |
| United States, Texas | |
| Womens Hospital of Texas | |
| Houston, Texas, United States, 77054 | |
| United States, Washington | |
| Sacred Heart Medical Center | |
| Spokane, Washington, United States, 99204 | |
Sponsors and Collaborators
American Medical Systems
Investigators
| Principal Investigator: | Anders Mellgren, MD | Abbott Northwestern Medical Center |
| Principal Investigator: | Dee Fenner, MD | University of Michigan |
More Information
No publications provided
| Responsible Party: | American Medical Systems |
| ClinicalTrials.gov Identifier: | NCT01090739 History of Changes |
| Other Study ID Numbers: | WC0807 |
| Study First Received: | March 19, 2010 |
| Last Updated: | December 12, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by American Medical Systems:
|
Fecal Incontinence |
Additional relevant MeSH terms:
|
Fecal Incontinence Rectal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013